Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Published byStefan Hansen Modified over 5 years ago

Similar presentations

Presentation on theme: "Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer."— Presentation transcript:

1 Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6).
Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). A, whole body gamma camera scan revealing left breast tumor (Tu), left axillary lymphadenopathy (LN), and liver (L). B, coronal SPECT image. C, parasagittal SPECT image revealing breast tumor (Tu), axillary lymphadenopathy (LN), and spleen (Spl). Kevin J. Harrington et al. Clin Cancer Res 2001;7: ©2001 by American Association for Cancer Research

Download ppt "Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer."

Similar presentations

Rearrangements of Gene A and Gene B

Rearrangements of Gene A and Gene B
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Precontrast coronal T1-weighted view shows metastatic nodules (long arrows) from breast cancer in the vicinity of the left BPL and another metastatic mass.

Precontrast coronal T1-weighted view shows metastatic nodules (long arrows) from breast cancer in the vicinity of the left BPL and another metastatic mass.
High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.

High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.

Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
Coronal (A) and axial (B) contrast-enhanced T1-weighted MR images and an axial DWI (C) and ADC map (D) in a patient with primary dural B-cell lymphoma.

Coronal (A) and axial (B) contrast-enhanced T1-weighted MR images and an axial DWI (C) and ADC map (D) in a patient with primary dural B-cell lymphoma.
Off-midline non-contrast-enhanced sagittal T1-weighted MR image (600/12/1) in a 48-year-old woman with breast cancer who presented with headache and fatigue.

Off-midline non-contrast-enhanced sagittal T1-weighted MR image (600/12/1) in a 48-year-old woman with breast cancer who presented with headache and fatigue.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
FAK overexpression in invasive human breast cancer and DCIS

FAK overexpression in invasive human breast cancer and DCIS
Frequent alterations identified and potential actionability.

Frequent alterations identified and potential actionability.
AXL is not expressed in human prostate tumors.

AXL is not expressed in human prostate tumors.
Matriptase-2 inhibited breast tumor development in vivo.

Matriptase-2 inhibited breast tumor development in vivo.
Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.
FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.
MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Similar presentations

Ads by Google